Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PT 001 - Pandion Therapeutics

Next Previous
X
Search
Drug Profile

PT 001 - Pandion Therapeutics

Alternative Names: MAdCAM PD-1 agonist; MAdCAM-tethered PD-1 Agonist; PD-1 MAdCAM Bifunctional Antibody; PD-1A07T; PT-001 - Pandion Therapeutics

Latest Information Update: 28 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pandion Therapeutics
  • Class Antihyperglycaemics; Bispecific antibodies; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Programmed cell death 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus
  • No development reported Autoimmune disorders

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
  • 01 Apr 2021 Pandion Therapeutics has been acquired by Merck & Co
  • 22 Feb 2021 Preclinical trials in Type 1 diabetes mellitus in USA (IV) before February 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top